NCT00022958Unknown不适用
Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 试验地点
- 1
研究概览
简要总结
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00022880Corixa Corporation30
Unknown
2 期
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOPNon-Hodgkin's LymphomaNCT00022932Corixa Corporation
已完成
2 期
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT00022945Corixa Corporation
已完成
1 期
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementLymphoma, Non-HodgkinNCT00992758GlaxoSmithKline11
已完成
2 期
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received RituximabLymphoma, Non-HodgkinNCT00996593GlaxoSmithKline43